TWD
CPRX

True Wealth Design’s Catalyst Pharmaceutical CPRX Stock Holding History

True Wealth Design’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-116
Closed -$2.52K – 2752
2025
Q2 		$2.52K Sell
116
-120
-51% -$2.83K ﹤0.01% 1084
2025
Q1 		$5.72K Hold
236
– – ﹤0.01% 643
2024
Q4 		$4.93K Buy
236
+22
+10% +$473 ﹤0.01% 535
2024
Q3 		$4.25K Buy
+214
New +$3.97K ﹤0.01% 596

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

True Wealth Design's CPRX Position: Q3 2025 in Review

True Wealth Design sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 116 shares — an estimated $2.52K sold.

True Wealth Design first reported a position in CPRX in Q3 2024 and held it in 4 quarters. The position peaked at $5.72K in Q1 2025. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • True Wealth Design reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • True Wealth Design sold 116 Catalyst Pharmaceutical shares in Q3 2025, an estimated $2.52K.
  • True Wealth Design first reported a position in Catalyst Pharmaceutical in Q3 2024 and held it in 4 quarters.
  • True Wealth Design's Catalyst Pharmaceutical position peaked at $5.72K in Q1 2025.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on True Wealth Design's 13F filing for Q3 2025, filed 21 Oct 2025.